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extraction. DNA was extracted by using the QIAamp DNA 
Stool Mini Kit (QIAGEN, Hilden, Germany) according to 
the manufacturer’s instructions.
Species-specific primers (online Technical Appendix 
Table, http://wwwnc.cdc.gov/EID/article/21/1/14-0136-
Techapp1.pdf) were designed to amplify short sequences 
of mitochondrial DNA. On the basis of primer specificity 
and amplicon size, we determined host and parasite species 
(online Technical Appendix Figure 1). DNA extraction and 
PCR were performed in a laboratory dedicated to environ-
mental samples (for a complete description of methods, see 
online Technical Appendix).
DNA was successfully extracted and amplified from 
119 (86.9%) of 137 fecal samples. Of usable samples, 28 
(23.5%) were from red foxes and 91 (76.5%) were from 
dogs. Two fox fecal samples (7.1%; 95% binomial CIs 
0.9%–23.5%) were infected with E. multilocularis tape-
worms; none of the dog samples were infected.
To verify parasite identification, we amplified DNA 
from the 2 E. multilocularis–positive samples with E. mul-
tilocularis–specific primers and sequenced the amplification 
products. To verify host species identification, we used prim-
ers that produced longer amplification products (327 and 197 
bp) than the corresponding PCR primers and sequenced am-
plification products from 5 fox samples and 5 dog samples. 
Sequencing procedures were performed according to the 
methods of Saarma et al. (10). 
Sequences from both E. multilocularis–positive sam-
ples showed 100% identity with an E. multilocularis tape-
worm sequence (GenBank accession no. AB018440) (on-
line Technical Appendix Figure 2). All sequenced fox and 
dog samples also belonged to the corresponding species.
To estimate the sensitivity of this noninvasive genetic 
method, we determined the number of E. multilocularis 
eggs necessary to obtain a positive PCR result (online 
Technical Appendix Figure 3). One egg was sufficient to 
give an E. multilocularis tapeworm–specific result.
In summary, we developed a noninvasive genetic 
method that identifies E. multilocularis tapeworms and 
their host species in carnivore fecal samples found in 
urban environments. Furthermore, these tapeworms can 
even be detected in fecal samples from red foxes when 
only 1 parasite egg is present. Thus, this method is highly 
sensitive and discriminatory and can be used with degrad-
ed fecal samples to monitor E. multilocularis tapeworms 
and their hosts.
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To the Editor: Intravenous artesunate is recommend-
ed by the World Health Organization as first-line treatment 
for severe malaria. While artemisinin-based therapies are 
well tolerated, recent studies have reported cases of severe 
delayed hemolysis after artesunate treatment for malaria 
(1–5). To date, all reported cases have been associated with 
the use of artesunate not produced under Good Manufac-
turing Practice (GMP) standards. The United States and 
Canada are the only countries that use GMP artesunate, and 
a recent review concluded that delayed hemolysis may be 
related to differences in GMP versus non-GMP artemisi-
nins (5). We report a case of severe delayed hemolysis after 
administration of GMP artesunate to treat a patient with 
severe malaria.
During October 2012, A previously healthy, 31-year-old 
Canadian-born man sought treatment at a hospital in Toronto, 
Ontario, Canada, after 3 days of fever and severe headaches. 
He had returned 10 days earlier from a 10-day work trip 
to South Sudan. He did not use malaria chemoprophylaxis 
while there but did sleep under an insecticide-treated net. 
During initial assessment, a blood smear showed Plasmodi-
um falciparum malaria with parasitemia of 22% (1,100,000 
parasites/mL) and the following levels: bilirubin, 88 (refer-
ence range 5–17) µmol/L; aminotransferase, 105 (reference 
range 10–38) U/L; creatinine, 130 (reference range 80–115) 
µmol/L; hemoglobin, 144 (reference range 140–160) g/L, 
and a platelet count of 17 × 109/L (reference range 150–450 
´ 109/L). In the emergency department, he was given 1 dose 
each of doxycycline, atovaquone/proguanil, and artemether/
lumefantrine; within an hour of ingestion of these drugs, he 
vomited. He was transferred to a tertiary level hospital for 
admission to the intensive care unit and exchange transfu-
sion. Intravenous artesunate was administered (2.4 mg/kg at 
0, 12, 24, and 48 h), then a 3-day course of oral atovaquone/
proguanil was ordered. On admission, his chest radiograph 
showed no abnormalities, and blood cultures were negative; 
his hemoglobin level was 125 g/L; no treatment was initi-
ated for decreased hemoglobin. Parasitemia was undetect-
able within 36 hours of admission to the intensive care unit. 
The patient was discharged 5 days later.
Four days after discharge, the patient returned to the 
tertiary level hospital seeking treatment. He reported that 
beginning 2 days after discharge, he had fever and “mer-
lot-colored” urine. On admission, he was noted to be jaun-
diced. Laboratory values included levels of bilirubin of 89 
µmol/L, lactate dehydrogenase (LDH) of 1,976 (reference 
120–240) U/L, hemoglobin of 81 g/L and marked hemo-
globinuria. Multiple thick and thin blood smears were neg-
ative for Plasmodium spp. 
During the course of his second admission, he required 
8 blood transfusions to maintain his hemoglobin level 
above 75 g/L. He continued to have unexplained hemoly-
sis and hemoglobinuria: laboratory results showed a nadir 
of hemoglobin at 68 g/L and an LDH peak of 3,429 U/L 
and a low haptoglobin level (<0.12 g/L [reference 0.3–2.0 
g/L]). His glucose-6-phosphate dehydrogenase level was 
within reference range. Supportive therapy was continued, 
and hemolysis ceased spontaneously 10 days after onset. 
When seen during a follow-up visit 6 weeks later, he was 
asymptomatic and his hemoglobin level was 135 g/L. Pre- 
and post-transfusion and follow-up testing did not show 
evidence of red blood cell alloantibodies, making the pos-
sibility of a delayed hemolytic transfusion reaction unlike-
ly. Serologic tests showed that the he was also positive for 
causative organisms for schistosomiasis, strongyloidiasis, 
and Q fever. These diagnoses were consistent with past in-
fections and were not considered to be contributory to the 
current severe hemolytic event.
In all previous case reports of delayed hemolysis, pa-
tients received World Health Organization–prequalified, but 
not GMP-certified, artesunate (1–5). In this report, the paren-
teral drug used was GMP certified and produced by the US 
Army Medical Materiel Development Activity. A diagnosis 
of artesunate-associated hemolysis was made in this case 
based on the temporal relationship with therapy and the ab-
sence of other identified causes of intravascular hemolysis. 
His time course of hemolysis after treatment corresponds 
with recent case series in Europe (1–4): his hemoglobin level 
reached a nadir at approximately day 15. The outcome of this 
case corresponds with a proposed case definition by Rolling 
and colleagues to distinguish artesunate-related hemolysis 
from that attributable to malaria infection alone (4). 
We suggest a case definition whereby a decrease in 
hemoglobin combined with an increase in LDH between 
week 2 and 3 is characteristic of delayed hemolysis as-
sociated with artesunate. Because treatment for severe 
malaria is not given as monotherapy, we cannot exclude 
a potential contributory role of the other antimalarial 
agents he received. However, severe intravascular he-
molysis has rarely been reported in relationship to these 
agents. Additionally, we cannot exclude a potential role 
for drug-induced immune hemolysis. Nonetheless, given 
the severity of the hemolysis and the delayed onset, health 
care workers should be cognizant of this late, potentially 
life-threatening complication of artemisinin-based thera-
py. All patients treated with artesunate for severe malaria 
should be monitored for 4 weeks and evaluated for hemo-
lytic anemia.
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To the Editor: Melioidosis is increasingly being rec-
ognized in tropical and subtropical areas worldwide; the 
world’s 2 major endemic foci are Thailand and northern 
Australia (1,2). Phylogenetic analyses of Burkholderia 
pseudomallei isolates, performed by using multilocus se-
quence typing (MLST) (3), have led to phylogeographic 
associations that can be used to track melioidosis epidem-
ics (4). However, in contrast to the previous separation of 
B. pseudomallei into 2 phylogenetic groups (Australia and 
Southeast Asia/rest of the world) (5), we report an MLST 
sequence type (ST) that seems to be present in northern 
Australia, Taiwan, and southern China.
In mainland China, melioidosis was first reported in 
1990 (6) and is now known to be endemic to several tropi-
cal provinces, including Hainan, a southern island province 
close to Southeast Asia. Since 2008, cases of melioidosis in 
Hainan have escalated; from July 2008 through July 2012, 
a total of 110 cases were microbiologically diagnosed at 
2 general hospitals (Sanya People’s Hospital and Haikou 
Municipal Hospital). 
We characterized clinical isolates of B. pseudomallei 
from the 110 cases by using MLST, pulsed-field gel elec-
trophoresis (PFGE), and 4-locus multilocus variable-number 
tandem-repeat analysis (MLVA-4) (3,7,8). MLST revealed 
40 STs, 39 of which were consistent with STs from Southeast 
Asia, as evident from the global B. pseudomallei MLST da-
tabase (http://bpseudomallei.mlst.net/). A single ST, ST562, 
which accounted for 3 cases in Hainan, was previously de-
scribed on the global database as being from Australia; the 20 
isolates from humans and 10 isolates from the environment 
deposited until September 1, 2014, all from Australia, had 
been isolated from 2005 through 2012. Although not depos-
ited in the global MLST database, ST562 has also recently 
been reported from Taiwan (7). Among the 253 isolates of B. 
pseudomallei collected in Taiwan during 2004–2010, 1 clini-
cal isolate and 9 environmental isolates were described as 
being ST562. Moreover, these 10 ST562 isolates displayed a 
unique PFGE pulsotype, distinct from that of other B. pseu-
domallei strains from Taiwan (7).
Of the 3 patients from Hainan from whom ST562 
strains were isolated, 2 resided in the city of Sanya and 1 
in the neighboring city of Lingshui (online Technical Ap-
pendix, http://wwwnc.cdc.gov/EID/article/21/1/14-0156- 
Techapp1.pdf); all denied a history of foreign travel, they 
shared no common risk factors, and all survived the in-
fection. Further analysis of ST562, performed by using 
eBURST-based (http://eburst.mlst.net/) population analy-
sis of the MLST dataset, showed that ST562 is a single-lo-
cus variant of ST167, which is represented on the MLST 
dataset by multiple human and environmental isolates 
from Thailand and to date by 1 human isolate from Cam-
bodia. ST167 accounted for 1 of the 110 B. pseudomallei 
strains from Hainan. The narK locus of ST167contains 
allele 3 instead of allele 29, as seen in ST562; 3 base dif-
ferences are found in allele 3: C72T (C→T position 72), 
C126T, and A435G. According to PFGE, the 3 ST562 
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